Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMS Medical has received a recommendation from the Data Safety Monitoring Board to continue MAESTRO-01, its pivotal Phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.
Subscribe to our email newsletter
This was the eighth of several regularly scheduled reviews by the Data Safety Monitoring Board (DSMB), including the planned in-depth interim safety analysis, held in April 2007, on the first 100 patients enrolled in the study who had completed 12 months of treatment. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.
BioMS Medical’s lead technology, MBP8298, is being evaluated in two pivotal Phase III clinical trials for secondary progressive multiple sclerosis (MS) patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the US. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01.